Friday, 9 May 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 09 May 2025
News

Big plans for ex-Novartis drug

Posted 29 April 2025 AM

Newly established Pharming Australia has its eyes set on turning up the clinical management of activated phosphoinositide 3-kinase delta syndrome in Australia with its newly approved oral PI3K delta inhibitor Joenja.

The Netherlands-headquartered company, which acquired Joenja from Novartis in 2019 is currently in the set-up and pre-launch phase in Australia, with a dedicated core team of three Pharming employees.

To see the whole article, please login

Popular

What downturn? Pharma is back
How leaders can fix disengagement
Who's industry's 'Most Influential'?
Drug flood overwhelming HCPs
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home